KRAS and flatulence: Recently, Selenica et al. examined 68 cases of GAS and discovered that most somatic mutations occurred in TP53 (41%), CDKN2A (18%), KRAS (18%), and STK11 (10%), with potentially targetable mutations identified in ERBB3 (10%), ERBB2 (8%), and BRAF (4%) [74].